Miriam Redrado

6PUBLICATIONS
43CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer cell biologyMolecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 25, 2025
Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy.

Esther Redin, Nerea Otegui, Mirentxu Santos

|Jan 03, 2025
Spatial expression of fibroblast activation protein-α in clear cell renal cell carcinomas revealed by multiplex immunoprofiling analysis of the tumor microenvironment.

Gorka Larrinaga, Miriam Redrado, Ana Loizaga-Iriarte

|Jun 13, 2023
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.

Francisco Exposito, Miriam Redrado, Maeva Houry

|Sep 17, 2021
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.

Clément Anfray, Francesco Mainini, Elisabeth Digifico

|Jul 02, 2021
Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy.

Emilio Esteban, Francisco Exposito, Guillermo Crespo

|Mar 04, 2021
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.

Esther Redin, Irati Garmendia, Teresa Lozano

Pageof 1

Frequent Collaborators

4 joint publications

Francisco Exposito

4 joint publications

Alfonso Calvo

3 joint publications

Diego Serrano

2 joint publications

Juan Lasarte